Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy
NCT ID: NCT00381719
Last Updated: 2008-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
330 participants
INTERVENTIONAL
2006-10-31
2007-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Study of GW493838, an Adenosine A1 Agonist, in Peripheral Neuropathic Pain
NCT00376454
Safety and Efficacy of AGN201781 in Neuropathic Pain
NCT00533351
A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic Pain
NCT00375960
A Study of Single Dose Pain Therapy in Patients With Painful Diabetic Neuropathy (0000-115)
NCT00837941
A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain
NCT00548925
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
3 mg
AGN 203818
3 mg Capsule twice daily for 4 weeks
2
20 mg
AGN 203818
20 mg Capsule twice daily for 4 weeks
3
60 mg
AGN 203818
60 mg Capsule twice daily for 4 weeks
4
Placebo
placebo capsule
Capsule twice daily for 4 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AGN 203818
3 mg Capsule twice daily for 4 weeks
AGN 203818
20 mg Capsule twice daily for 4 weeks
AGN 203818
60 mg Capsule twice daily for 4 weeks
placebo capsule
Capsule twice daily for 4 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Moderate to severe neuropathic pain
Exclusion Criteria
* Pregnant or nursing females
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Allergan, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tacoma, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
203818-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.